Similar articles for PMID: 23940302

Year	Number of Results
2005	1
2006	1
2007	1
2008	2
2009	1
2010	3
2011	10
2012	25
2013	18
2014	16
2015	17
2016	6
2017	1
2018	2
2020	4
2024	0

1

Standards for reporting PET clinical trials.

Eary JF, Krohn KA. Eary JF, et al. J Nucl Med. 2013 Sep;54(9):1516-7. doi: 10.2967/jnumed.113.127845. Epub 2013 Aug 12. J Nucl Med. 2013. PMID: 23940302 Free PMC article. No abstract available.

2

The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review.

Patel K, Hadar N, Lee J, Siegel BA, Hillner BE, Lau J. Patel K, et al. J Nucl Med. 2013 Sep;54(9):1518-27. doi: 10.2967/jnumed.112.119362. Epub 2013 Jun 17. J Nucl Med. 2013. PMID: 23776200 Free PMC article.

3

Surveillance of cancer patients with imaging: self-evident or evidence-based?

Weber WA, Wahl RL. Weber WA, et al. J Nucl Med. 2013 Sep;54(9):1513-5. doi: 10.2967/jnumed.113.127183. Epub 2013 Aug 8. J Nucl Med. 2013. PMID: 23929825 Free article. No abstract available.

4

Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?

Gallamini A, Kostakoglu L. Gallamini A, et al. Haematologica. 2012 Jun;97(6):797-9. doi: 10.3324/haematol.2012.063909. Haematologica. 2012. PMID: 22665528 Free PMC article. No abstract available.

5

Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.

Basu S, Saboury B, Torigian DA, Alavi A. Basu S, et al. Mol Imaging Biol. 2011 Oct;13(5):801-11. doi: 10.1007/s11307-010-0426-6. Mol Imaging Biol. 2011. PMID: 21136185 Review.

6

Detecting residual fluorine 18 from a medical PET-CT procedure during population whole body counter screening in Fukushima.

Nishikawa Y, Tsubokura M, Kato S, Ishii T, Saito Y. Nishikawa Y, et al. Disaster Med Public Health Prep. 2014 Dec;8(6):469-70. doi: 10.1017/dmp.2014.135. Disaster Med Public Health Prep. 2014. PMID: 25859688 No abstract available.

7

[Usefulness of PET-CAT in oncology].

Carreras Delgado JL. Carreras Delgado JL. An R Acad Nac Med (Madr). 2010;127(4):693-6; discussion 696-9. An R Acad Nac Med (Madr). 2010. PMID: 22263354 Spanish. No abstract available.

8

Incidence, appropriateness, and consequences of recommendations for additional imaging tests in oncological PET/CT reports.

Shinagare AB, Shyn PB, Sadow CA, Wasser EJ, Catalano P. Shinagare AB, et al. Clin Radiol. 2013 Feb;68(2):155-61. doi: 10.1016/j.crad.2012.06.111. Epub 2012 Aug 11. Clin Radiol. 2013. PMID: 22892243

9

Patient comfort during positron emission tomography/magnetic resonance and positron emission tomography/computed tomography examinations: subjective assessments with visual analog scales.

Gückel B, Gatidis S, Enck P, Schäfer J, Bisdas S, Pfannenberg C, Schwenzer N. Gückel B, et al. Invest Radiol. 2015 Oct;50(10):726-32. doi: 10.1097/RLI.0000000000000177. Invest Radiol. 2015. PMID: 26039772

10

Positron emission tomography computed tomography in oncology.

Drake B, Cook GJ. Drake B, et al. Br J Hosp Med (Lond). 2011 Nov;72(11):631-7. doi: 10.12968/hmed.2011.72.11.631. Br J Hosp Med (Lond). 2011. PMID: 22083005 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

95 results

Results by year